Clinical Trials

129 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT04380636 2026-05-15

MK-7339-012

870 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06623422 2026-05-15

INTerpath-009

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06417814 2026-05-14

TROPION-Lung15

744 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-05-13

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

630 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT06793215 2026-05-11

Krascendo 2

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05870319 2026-05-08

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

376 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-05-05

REZILIENT4

360 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

48 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07524257 2026-05-04

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04092283 2026-05-01

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05687266 2026-04-22

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

354 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05555732 2026-03-25

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled